Advancing tuberculosis detection: From patient stories to innovative NGS solutions
Tuberculosis remains one of the leading infectious diseases worldwide, requiring continuous innovation in detection and treatment. Behind the global fight against TB are both powerful human stories and groundbreaking scientific advances that are transforming patient care.
A tuberculosis survivor’s story
The story of a tuberculosis survivor illustrates the real-life challenges faced by TB patients. Like many others, this patient experienced the difficulties of delayed detection, long treatment regimens, and the uncertainty that often accompanies the disease.
This recovery underscores a critical message: early and accurate tuberculosis detection is essential for improving patient outcomes and reducing transmission. Stories like this highlight the urgent need for reliable and rapid screening tools in the global fight against TB.
Strengthening TB control in South Africa
South Africa has been at the forefront of tuberculosis control through its National Tuberculosis Programme and a range of public health and research initiatives. These efforts aim to:
- Improve access to timely and accurate TB detection and treatment
- Support research and the dissemination of scientific knowledge
- Strengthen the capacity of healthcare professionals to manage tuberculosis effectively
Together, these initiatives play a critical role in addressing both drug-sensitive and drug-resistant tuberculosis, which remains a major global health challenge.
GenoScreen & Illumina: A partnership driving innovation in drug-resistant TB detection
In line with these global efforts, GenoScreen is proud to partner with Illumina to provide advanced tuberculosis detection solutions. This co-marketing and reselling collaboration in select countries aims to deliver faster, more accurate detection of drug resistance, ultimately improving patient care and treatment success rates.
Deeplex® Myc-TB: Next-Generation Sequencing for tuberculosis drug resistance testing
Deeplex® Myc-TB is a WHO-recommended targeted NGS assay for tuberculosis drug resistance testing, delivering culture-free molecular susceptibility results for 15 anti-TB drugs in under 48 hours through deep sequencing and automated web-based analysis.
Furthermore, this solution can detect tuberculosis heteroresistance down to 3%, and also identifies Mycobacterium tuberculosis complex (sub)lineages and spoligotypes, as well as more than 100 species of non-tuberculous mycobacteria (NTM).
By providing rapid and extensive prediction of genetic resistance to anti-tuberculosis drugs, this innovative test represents a powerful tool for guiding effective therapeutic management of patients suffering from tuberculosis. Thus, the NGS-based drug resistance testing for tuberculosis provided by Deeplex® Myc-TB allows clinicians to detect both first- and second-line drug resistance.